Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HAEMONETICS CORPHAE · Entity 3953 | EVP, Chief Commercial Officer | May 15, 2026 | May 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HAEMONETICS CORP
Report date May 15, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,882 |
Last balance in matching sequence
After 2026-05-15 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-05-15 · Tax withholding · Disposed 879 · Balance 12,347 F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2: This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026. Row 2 · 2026-05-15 · Grant · Acquired 27,535 · Balance 39,882 F3: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant. F4: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2: This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
F2: This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.
F3: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
F4: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 19, 2026 21:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 27,535 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000313143-26-000044 · form4.xml · nonDerivative · entry 2 Galvin Roy · CIK 0001950021 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,882 F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant. F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026. Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 879 | $56.29 | $49,478.91 |
DisclosureSEC source: 0000313143-26-000044 · form4.xml · nonDerivative · entry 1 Galvin Roy · CIK 0001950021 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,347 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026. Read SEC document |
| October 31, 2025 Filed Nov 3, 2025 21:19 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 145 | $50.01 | $7,251.45 |
DisclosureSEC source: 0000313143-25-000064 · form4.xml · nonDerivative · entry 1 Galvin Roy · CIK 0001950021 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,811 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported as well as 24 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2025. Read SEC document |
| May 16, 2025 Filed May 19, 2025 21:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 257 | $70.31 | $18,069.67 |
DisclosureSEC source: 0001127602-25-014938 · form4.xml · nonDerivative · entry 2 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,243 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported as well as 328 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2025. Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:21 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,626 | $0.00 Strike: $70.31 | $0.00 |
DisclosureSEC source: 0001127602-25-015061 · form4.xml · derivative · entry 2 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,626 Underlying: Common Stock · 14,626 shares Expires 2032-05-16 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:21 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 6,755 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-015061 · form4.xml · nonDerivative · entry 1 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,998 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2025 Filed Jun 13, 2025 20:21 UTC Amendment | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 12,317 | $0.00 Strike: $70.31 | $0.00 |
DisclosureSEC source: 0001127602-25-017492 · form4a.xml · derivative · entry 2 Galvin Roy · CIK 0001950021 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,317 Underlying: Common Stock · 12,317 shares Expires 2032-05-16 F5 · shares: On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of options awarded to be 14,626 instead of 12,317. This net decrease of 2,309 options will be reflected in future filings by the reporting person. F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 16, 2025 Filed Jun 13, 2025 20:21 UTC Amendment | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 5,689 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-017492 · form4a.xml · nonDerivative · entry 1 Galvin Roy · CIK 0001950021 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,932 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · shares: On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of RSUs awarded to be 6,755 instead of 5,689. This net decrease of 1,066 RSUs, and the corresponding change in securities beneficially owned by the reporting person, will be reflected in future filings by the reporting person. F3 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F4 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 201 | $69.38 | $13,945.38 |
DisclosureSEC source: 0001127602-25-014938 · form4.xml · nonDerivative · entry 1 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported as well as 328 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2025. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 161 | $71.48 | $11,508.28 |
DisclosureSEC source: 0001127602-24-026473 · form4.xml · nonDerivative · entry 1 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,373 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported as well as 124 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2024. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 6,313 | $0.00 Strike: $95.73 | $0.00 |
DisclosureSEC source: 0001127602-24-016166 · form4.xml · derivative · entry 2 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,313 Underlying: Common Stock · 6,313 shares Expires 2031-05-17 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-016166 · form4.xml · nonDerivative · entry 1 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,410 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:08 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 214 | $96.49 | $20,648.86 |
DisclosureSEC source: 0001127602-24-015882 · form4.xml · nonDerivative · entry 1 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,538 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported as well as 157 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2024. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 160 | $86.39 | $13,822.40 |
DisclosureSEC source: 0001127602-23-026759 · form4.xml · nonDerivative · entry 1 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,595 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported as well as 66 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2023. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:28 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,068 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0001127602-23-015934 · form4.xml · derivative · entry 2 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,068 Underlying: Common Stock · 5,068 shares Expires 2030-05-15 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:28 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,243 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015934 · form4.xml · nonDerivative · entry 1 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,689 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported as well as 64 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 28, 2023. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:54 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,263 | $0.00 Strike: $83.96 | $0.00 |
DisclosureSEC source: 0001127602-22-024920 · form4.xml · derivative · entry 2 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,263 Underlying: Common Stock · 5,263 shares Expires 2029-11-01 F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:54 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,382 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-024920 · form4.xml · nonDerivative · entry 1 Galvin Roy · CIK 0001950021 · President, Global Plasma & BC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,382 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.